The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
Open accessAbstract
Purpose: The outcome of patients diagnosed with advanced gastrointestinal stromal tumor (GIST) and treated long-term with imatinib mesylate is unknown. A previous report of a randomized phase II trial of imatinib mesylate in patients with incurable GIST detailed high response rates at both the 400 and the 600 mg/d dose levels. We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status. Patients and Methods: Patients with advanced GIST were enrolled onto an open-label, multicenter trial and were randomly assigned (1:1) to receive imatinib 400 versus 600 mg/d. Data were prospectively collected on KIT mutational status, total tumor area, and other potential prognostic factors. Patients were followed for a median of 63 months. Results: One hundred forty-seven patients were enrolled: 73 were in arm A (imatinib 400 mg/d), and 74 were in arm B (imatinib 600 mg/d). Response rates, median progression-free survival, and median overall survival were essentially identical on both arms, and median survival was 57 months for all patients. Forty-one patients overall (28%) remained on the drug long-term. Female sex, the presence of an exon 11 mutation, and normal albumin and neutrophil levels were independently associated with better survival. Conclusion: Nearly 50% of patients with advanced GIST who were treated with imatinib mesylate survived for more than 5 years, regardless of a 400 or 600 mg/d starting dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citationKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Self-citationJoensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationNilsson, B., Bümming, P., Meis‐Kindblom, J. M., Odén, A., Dortok, A., Gustavsson, B., Sablinska, K., & Kindblom, L. (2005) · Cancer · doi:10.1002/cncr.20862 · Cited by 1,272
Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citationBuchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J.-Y., Leyvraz, S., Stul, M., Casali, P. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.030 · Cited by 892
Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., & Demetri, G. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204704 · Cited by 695
Self-citationSouthwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
We Should Desist Using RECIST, at Least in GIST
Benjamin, R. S., Choi, H., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Charnsangavej, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3411 · Cited by 559
Zalcberg, J. R., Verweij, J., Casali, P. G., Le Cesne, A., Reichardt, P., Blay, J.-Y., Schlemmer, M., Van Glabbeke, M., Brown, M., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.04.034 · Cited by 378
Tryggvason, G., Gíslason, H. G., Magnússon, M. K., & Jónasson, J. G. (2005) · International Journal of Cancer · doi:10.1002/ijc.21167 · Cited by 358
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A. L., Cambareri, A. C., Zannettino, A. C. W., Miller, B. L., Doherty, K. V., Hughes, T. P., & Lyons, A. B. (2005) · Blood · doi:10.1182/blood-2004-10-3967 · Cited by 284
Van Glabbeke, M., Verweij, J., Casali, P. G., Le Cesne, A., Hohenberger, P., Ray-Coquard, I., Schlemmer, M., van Oosterom, A. T., Goldstein, D., Sciot, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.601 · Cited by 280
ARG tyrosine kinase activity is inhibited by STI571
Okuda, K., Weisberg, E., Gilliland, D. G., & Griffin, J. D. (2001) · Blood · doi:10.1182/blood.v97.8.2440 · Cited by 257
State-of-the Art Therapy for Gastrointestinal Stromal Tumors
Blanke, C. D., & Corless, C. L. (2005) · Cancer Investigation · doi:10.1081/cnv-200055972 · Cited by 69
Self-citation
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
DeMatteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60500-6 · Cited by 1,369
Self-citationNCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Self-citation
Metadata
- Authors
- Blanke, C. D., Demetri, G. D., von Mehren, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., Corless, C. L., Fletcher, C. D. M., Roberts, P. J., Heinz, D., Wehre, E., Nikolova, Z., & Joensuu, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-02-01
- Volume
- 26
- Issue
- 4
- Pages
- 620-625
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2115504770
- Cited by
- 996
- References
- 17
- FWCI
- 65.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.